当代医学
噹代醫學
당대의학
CHINA CONTEMPORARY MEDICINE
2014年
19期
54-55
,共2页
序贯和同步%放化疗%结直肠癌%疗效
序貫和同步%放化療%結直腸癌%療效
서관화동보%방화료%결직장암%료효
Sequential and synchronous%Chemotherapy%Colorectal cancer%Curative effect
对比序贯放化疗和同步放化疗用于结直肠癌治疗的临床效果。方法回顾性分析河南省濮阳市人民医院60例结直肠癌患者临床资料，其中Ⅱ期患者20例，依照入院顺序随机平均分为A组和B组；Ⅲ期患者40例，依照入院顺序随机平均分为C组和D组，A、C组予以序贯放化疗，B、D组予以同步放化疗，对比A、C组和B、D组疗效。结果Ⅱ期序贯、同步放化疗临床效果对比2组各阶段总生存率及无进展生存率无差异。A、B组各阶段总生存率及无进展生存率无差异，D组同步放化疗后1年总生存率、无进展生存率分别为90%、80%，3年总生存率、无进展生存率分别为70%、55%，均明显高于C组（P＜0.05）。A、C组序贯放化疗与B、D组对应毒副作用发生率对比无差异。结论同步放化疗方案治疗Ⅲ期结直肠癌生存率更高、毒副作用与序贯放化疗方案相当，安全有效。
對比序貫放化療和同步放化療用于結直腸癌治療的臨床效果。方法迴顧性分析河南省濮暘市人民醫院60例結直腸癌患者臨床資料，其中Ⅱ期患者20例，依照入院順序隨機平均分為A組和B組；Ⅲ期患者40例，依照入院順序隨機平均分為C組和D組，A、C組予以序貫放化療，B、D組予以同步放化療，對比A、C組和B、D組療效。結果Ⅱ期序貫、同步放化療臨床效果對比2組各階段總生存率及無進展生存率無差異。A、B組各階段總生存率及無進展生存率無差異，D組同步放化療後1年總生存率、無進展生存率分彆為90%、80%，3年總生存率、無進展生存率分彆為70%、55%，均明顯高于C組（P＜0.05）。A、C組序貫放化療與B、D組對應毒副作用髮生率對比無差異。結論同步放化療方案治療Ⅲ期結直腸癌生存率更高、毒副作用與序貫放化療方案相噹，安全有效。
대비서관방화료화동보방화료용우결직장암치료적림상효과。방법회고성분석하남성복양시인민의원60례결직장암환자림상자료，기중Ⅱ기환자20례，의조입원순서수궤평균분위A조화B조；Ⅲ기환자40례，의조입원순서수궤평균분위C조화D조，A、C조여이서관방화료，B、D조여이동보방화료，대비A、C조화B、D조료효。결과Ⅱ기서관、동보방화료림상효과대비2조각계단총생존솔급무진전생존솔무차이。A、B조각계단총생존솔급무진전생존솔무차이，D조동보방화료후1년총생존솔、무진전생존솔분별위90%、80%，3년총생존솔、무진전생존솔분별위70%、55%，균명현고우C조（P＜0.05）。A、C조서관방화료여B、D조대응독부작용발생솔대비무차이。결론동보방화료방안치료Ⅲ기결직장암생존솔경고、독부작용여서관방화료방안상당，안전유효。
Objective To compare the sequential chemoradiotherapy andconcurrent chemoradiotherapy for treatment of rectal cancer.Methods A total of 60 cases of patients with colorectal cancer, 20 cases of stage II patients,divided into A group and B group; 40 cases in stage III patients, divided into C group and D group, A, C group was treated with sequential chemotherapy, B, D group was treated with radiotherapy and chemotherapy. Results The totalsurvival rate of A, B group of each stage and progression free survival was no difference , D group of 1 years, 3 year overall survival, progression free survival rate was significantly higher than that in C group (P<0.05). A, B, C group and D group, the incidence of adverse effects compared with no difference.Conclusion Radiotherapy and chemotherapy in the treatment of stage III colorectal cancer survival rate is higher, side effects andsequential chemotherapy scheme.
